SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Relay Therapeutics Reports Q3 Net Loss

Q3 operating expenses were USD 90.245 million. Net income was below zero, versus the IBES estimate.

RLAY

Related stories